Copyright
©The Author(s) 2025.
World J Cardiol. Feb 26, 2025; 17(2): 102308
Published online Feb 26, 2025. doi: 10.4330/wjc.v17.i2.102308
Published online Feb 26, 2025. doi: 10.4330/wjc.v17.i2.102308
Table 1 Acid sphingomyelinase/ceramide functional inhibitors
Serial number | FIASMAs | Current functional or therapeutic disease | Potential therapeutic metabolic disease |
1 | Amitriptyline | Depression | Diabetic cardiomyopathy |
2 | Desipramine | Depression | Insulin resistance. Diabetes |
3 | Doxepin | Depression | Diabetes |
4 | Imipramine | Depression | Diabetic cardiomyopathy |
5 | Alpha-mangostin | Anti-cancer, antibacterial, anti-inflammation, antioxidant | Vascular endothelial injury. Cardiovascular disease |
6 | Empagliflozin | Diabetes | Cardiovascular disease |
- Citation: Wang HN, Wang Y, Zhang SY, Bai L. Emerging roles of the acid sphingomyelinase/ceramide pathway in metabolic and cardiovascular diseases: Mechanistic insights and therapeutic implications. World J Cardiol 2025; 17(2): 102308
- URL: https://www.wjgnet.com/1949-8462/full/v17/i2/102308.htm
- DOI: https://dx.doi.org/10.4330/wjc.v17.i2.102308